Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Down 21.0% in December

Alto Neuroscience, Inc. (NYSE:ANRO) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 2,198,907 shares, a decrease of 21.0% from the December 15th total of 2,781,726 shares. Based on an average daily trading volume, of 490,970 shares, the days-to-cover ratio is presently 4.5 days. Currently, 7.1% of the company’s stock are sold short. Currently, 7.1% of the company’s stock are sold short. Based on an average daily trading volume, of 490,970 shares, the days-to-cover ratio is presently 4.5 days.

Alto Neuroscience Stock Up 1.1%

NYSE:ANRO traded up $0.19 during midday trading on Friday, reaching $17.21. 206,782 shares of the stock traded hands, compared to its average volume of 276,934. The stock has a market capitalization of $534.74 million, a PE ratio of -7.52 and a beta of 2.78. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $20.91. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42. The business has a 50-day moving average of $15.66 and a two-hundred day moving average of $8.78.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14. On average, equities analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANRO has been the subject of several recent research reports. Robert W. Baird lifted their price objective on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Chardan Capital boosted their price target on shares of Alto Neuroscience from $15.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 5th. Wall Street Zen raised shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Finally, BTIG Research initiated coverage on shares of Alto Neuroscience in a research note on Monday, November 17th. They issued a “buy” rating and a $27.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.33.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can purchased a new stake in shares of Alto Neuroscience during the second quarter worth about $25,000. Ground Swell Capital LLC purchased a new position in shares of Alto Neuroscience in the 2nd quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Alto Neuroscience in the 2nd quarter worth approximately $33,000. AlphaCore Capital LLC boosted its stake in Alto Neuroscience by 100.0% in the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in Alto Neuroscience during the 1st quarter worth approximately $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.